Despite difficult trading conditions anticipated in H2, Clinigen is set to deliver a better-than-expected underlying profit performance of c.2% for FY 2021. However, given currency impacts, we expect to lower our EBITDA and EPS FY 2021 and FY 2022 forecasts by c.2% and c.4% respectively. As we look into FY 2022, we see several drivers supporting growth, plus Proleukin newsflow that could drive a material re-rating in the stock. The stock is trading on 10x FY 2022 P/E. We reiterate our price target of £10.
Davy research
Davy ResearchAmryt Pharma - Fiscal year 2020 better across the board
Davy ResearchLufthansa - Restructuring and deleveraging will be a long and painful process
Davy ResearchVistry Group - Company makes very strong start to 2021
Davy ResearchMarket comment - Ireland’s unemployment rate steady at 5.8%
Davy ResearchEntain - Enters 2021 with good US momentum
Davy ResearchOrigin Enterprises - Controlling the controllables; cash flow the stand-out
Davy ResearchCairn Homes - FY results in line with guidance; no material changes likely to forecasts